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Introduction
Sepsis is a lethal syndrome characterized by infection and organ 
dysfunction, affecting approximately 19 million individuals per 
year worldwide (1). The heterogeneity of septic patients makes 
clinical characteristics and disease process extremely variable 
(2, 3). Awareness of the precise characteristics and pathogene-
sis is essential for effective antisepsis treatment. In this context, 
improving definition of patient phenotype is needed to allow for 
individualized management strategies matched to a patient’s 
molecular and biochemical profile. Nonalcoholic fatty liver dis-
ease (NAFLD) is the most common chronic liver disease in the 
world, affecting up to 30% of the adult population (4, 5). NAFLD 
encompasses a histological spectrum, ranging from simple steato-
sis to nonalcoholic steatohepatitis (NASH), the latter of which is 
characterized by advanced hepatic inflammation, endoplasmic 
reticulum (ER) stress, mitochondria malfunction, and fibrosis (6). 
The established 2-hit model postulates that liver fat buildup makes 
hepatocytes vulnerable to second injury (7). Accordingly, NAFLD 
is associated with adverse outcomes in many diseases (8–11).
In this study, we initially demonstrated a role of NAFLD in sep-
tic mortality in a large clinical cohort, supporting that compromised 
hepatic homeostasis is an important component of the maladaptive 
host response to sepsis. By investigating the underlying mecha-
nisms, we found that NAFLD is associated with impaired hepatic 
mitochondrial homeostasis and energetic metabolism, as well as 
the emergence of liver macrophages expressing triggering receptor 
expressed on myeloid cells-2 (TREM2). TREM2 is a lipid-binding 
cell surface receptor that transmits intracellular signals through the 
adapter DAP12. TREM2 has been previously shown to sustain met-
abolic fitness of microglia during Alzheimer’s disease and to sup-
port the ability of adipose tissue macrophages to control metabolic 
syndrome in high fat diet (HFD) (12–15). Using in vitro and in vivo 
models, we found that liver control of lipid overload involves a met-
abolic coordination between macrophages and hepatocytes that 
depends in part on TREM2. Trem2-deficient macrophages released 
exosomes (Exos) that impaired the mitochondria and energy supply 
of hepatocytes because of their high content of miR-106b-5p, which 
blocks Mfn2. TREM2 deficiency accelerated the progression of 
NAFLD and aggravated NAFLD-associated sepsis in vivo, whereas 
TREM2 overexpression conversely had a protective effect in these 
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Notably, the Type 2 diabetes comorbidity rate (27.91% vs. 8.1%, 
P < 0.001) and plasma glucose value (9.72 ± 4.14 vs. 8.4 ± 3.36, 
P = 0.0003) were higher in the NAFLD group compared with the 
non-NAFLD group (Supplemental Table 1). Type 2 diabetes has been 
demonstrated to increase sepsis mortality risk (20). We repeated the 
analysis after excluding these diabetic patients (456 remained). The 
28-day mortality (30.11% vs. 15.15%, P = 0.0015) and hospital mor-
tality (35.48% vs. 17.36%, P = 0.0003) were still significantly higher 
in the NAFLD group than in the non-NAFLD group (Supplemental 
Figure 1G). The same trend was observed in the diabetic patients 
(n = 68). The diabetes with NAFLD group had a higher tendency 
of 28-day mortality than did the diabetes without NAFLD group 
(28-day mortality: 38.89% vs. 21.88%, P = 0.19; hospital mortality: 
41.67% vs. 31.25%, P = 0.45, Supplemental Figure 1H). In the NAFLD 
group, the 28-day and hospital mortality in patients with and without 
diabetes were comparable (28-day mortality: 38.89% vs. 30.11%, P = 
0.40; hospital mortality: 41.67% vs. 35.48%, P = 0.55), indicating a 
strong link between NAFLD and septic mortality.
Patients with NAFLD had higher SOFA (8.39 ± 4.49 vs. 6.13 
± 3.53, P < 0.001) and APACHE II (15.94 ± 6.49 vs. 14.28 ± 5.26, 
P = 0.004) scores, and an increased need for immunomodula-
tor drugs (P < 0.001), ventilation (P < 0.001), renal replace treat-
ment (P < 0.001), and ICU days (P < 0.01) compared with patients 
without NAFLD (Supplemental Table 1). Alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST) levels in patients 
with NAFLD were numerically increased (ALT: 185.75 ± 638.95 
vs. 103.19 ± 386.38, P = 0.08; and AST: 167.78 ± 756.41 vs. 145.04 ± 
456.3, P = 0.07, respectively), although these differences were not 
statistically significant (Supplemental Table 1). Together, our results 
support that NAFLD is an independent risk factor for septic death.
Patients with NAFLD exhibit liver mitochondria dysfunction. We 
next explored the pathology underpinning mortality risk in septic 
patients with NAFLD. It has been shown that liver energetic metab-
olism shifts from glycolysis to long-chain fatty acid oxidation (FAO) 
during sepsis to preserve glucose stores for the brain and provide 
ATP for the peripheral tissue (21–23). Mitochondria are the pri-
mary site for FAO (24). Maladaptation of hepatic mitochondria 
has been shown to be a central feature of the transition from sim-
ple steatosis to NASH (25, 26). To investigate whether the defects 
of energy metabolism and/or mitochondria occurs in NAFLD, we 
first performed transcriptome analysis from livers of donors who 
underwent organ donation after cardiac death (DCD; 6 non-NA-
FLD donors, 5 NAFLD donors). In this screen, 462 transcripts were 
upregulated and 447 transcripts were downregulated in response 
to NAFLD (Figure 2A and Supplemental Data Set 1; GSE160022). 
Among these differentially expressed genes (DEGs) (Padj < 0.05), 
gene sets that contribute to endoplasmic reticulum stress, intrinsic 
apoptosis, and cytokine production were enriched in NAFLD livers. 
Conversely, gene sets that contribute to lipid metabolism were sup-
pressed in NAFLD livers, accompanied by deficient expression of 
the mitochondrial matrix enzymes (Figure 2, B and C).
Next, we assessed mitochondria damage by examining hepatic 
mitochondrial morphology and integrity in an independent NAFLD 
cohort (n = 7 in non-NAFLD group, n = 14 in NAFLD group). Hepato-
cytes in NAFLD samples displayed altered mitochondrial morpholo-
gy characterized by reduced size and excessive mitochondrial dam-
age compared with non-NAFLD controls, as shown by transmission 
models. These results demonstrate that NAFLD is a risk factor 
for sepsis, providing a basis for precision treatment, and identify 
TREM2-dependent hepatocyte-macrophage metabolic coordina-
tion as a mechanism that can be targeted to improve NAFLD and 
NAFLD-associated pathology, such as sepsis.
Results
NAFLD is an independent risk factor for hospital mortality in critically 
ill patients with sepsis. To investigate the contribution of NAFLD to 
the mortality of sepsis, we performed a prospective clinical cohort 
study. A total of 1307 patients diagnosed with sepsis according 
to Sepsis 3.0 criteria were encountered, of which 524 (40.09%) 
patients with sepsis who had computed tomography (CT) of the 
abdomen within 2 months prior to ICU admission or during ICU 
stay were included. The flow diagram of patient enrollment and 
exclusion is presented in Figure 1A. The CT diagnosis of hepatic ste-
atosis was made by measuring liver attenuation (LA) in Hounsfield 
units (HU). NAFLD was diagnosed when the LA value was ≤ 40 
HU (hepatic steatosis area > 30%, moderate-to-severe, Figure 1B, 
and refs. 16–19). Of these 524 septic patients, 129 (24.62%) were 
identified as NAFLD. The clinical characteristics of 524 adults with 
sepsis according to hepatic steatosis categories are summarized in 
Supplemental Table 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI135197DS1.
The primary outcomes were 28-day mortality and hospital 
mortality after admission to the ICU. Secondary outcomes were 
the differences in the need for ventilation, renal replacement ther-
apy (RRT), vasopressor infusions, immunomodulator drugs, and 
ICU care according to the hepatic steatosis categories at an inter-
im 28-day time point. Overall, the primary unfavorable outcome 
occurred in 104 (28-day mortality, 19.85%) and 121 (hospital mor-
tality, 23.09%) of 524 patients with sepsis.
The NAFLD cohort showed significantly increased 28-day mor-
tality and hospital mortality (32.56% vs. 15.7%, P < 0.0001; 37.21% 
vs. 18.48%, P < 0.0001, respectively) compared with the mortality 
of the non-NAFLD cohort (Figure 1, C and D). Multivariate logistic 
regression was further performed to estimate the effect of NAFLD 
on hospital mortality adjusted by age, sex, BMI, and site of infec-
tion, and it showed that NAFLD was an independent risk factor 
(Figure 1E). The adjusted OR of hospital mortality was 2.92 for the 
NAFLD group (95% confidence interval: 1.69–5.03, P < 0.001) (Fig-
ure 1E). Interestingly, the 28-day mortality and the hospital mortal-
ity of septic patients with NAFLD increased both in patients with 
low BMI (28-day mortality: 17.95% vs. 44.12%, P <0.0001; hospital 
mortality: 20.77% vs. 51.47%, P < 0.0001) and those with high BMI 
(28-day mortality: 9.91% vs. 19.67%, P = 0.0999; hospital mortali-
ty: 12.61% vs. 21.31%, P = 0.1877, Supplemental Figure 1, A and B). 
Of note, in the low BMI group, the mortality rate of patients with 
NAFLD was approximately 2- to 2.5-fold that of patients without 
NAFLD (Supplemental Figure 1, A and B). Moreover, in the NAFLD 
group, female patients with NAFLD and patients with NAFLD who 
were 65 years and older showed higher 28-day and hospital mortal-
ity than male patients with NAFLD (28-day mortality: 38.33% vs. 
27.54%, P = 0.26; hospital mortality: 46.67% vs. 28.99%, P = 0.046) 
and patients with NAFLD who were under age 65 (28-day mortal-
ity: 50.0% vs. 19.18%, P = 0.0003; hospital mortality: 50.0 % vs. 
27.40%, P = 0.01), respectively (Supplemental Figure 1, C–F).
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number of CD68+TREM2+ macrophages and the overall TREM2 
expression in the NAFLD donors were significantly increased com-
pared with controls (Figure 3, A and B). The same phenomenon was 
also observed in the livers of WT mice fed a HFD (Supplemental 
Figure 2A). Next, the monocyte-derived macrophages (MDMs) 
and Kupffer cells (KCs) were isolated from WT mice fed HFD for 
8 weeks, and qPCR confirmed the high expression of Trem2 in KCs 
(Supplemental Figure 2, B and C). It was recently reported that 
TREM2+ macrophages in the adipose tissue protect against adi-
pocyte hypertrophy caused by HFD (13). Thus, accumulation of 
TREM2+ macrophages in NAFLD may provide a defense mecha-
nism that attenuates liver dysmetabolism occurring in NAFLD.
TREM2 deficiency exacerbates liver mitochondria dysfunction 
in a NAFLD mouse model. To investigate whether TREM2 has a 
protective role against metabolic dysfunction in a mouse model 
of NAFLD, 8-week-old Trem2-deficient (Trem2–/–) and littermate 
WT mice were fed a normal chow diet (NCD) or a HFD for 8 weeks 
and their livers were excised and evaluated (Figure 4A). Upon 
electron microscopy (TEM) (Figure 2, D and E). Consistently, the 
NAFLD group (n = 21) exhibited reduced ATP content in the liv-
er and increased ALT and AST levels in the serum compared with 
the non-NAFLD group (n = 9, Figure 2F and Supplemental Table 2). 
Therefore, our data support that increased mortality risk in septic 
patients with NAFLD is associated with hepatic mitochondrial dys-
function, which impairs FAO and energy supply during septic insult.
Livers of patients with NAFLD and a mouse NAFLD model have 
abundant TREM2+ macrophages. Tissue-resident macrophages are 
the first responding immune cells to organ injury (27, 28). Livers in 
human NASH and a mouse model of NASH exhibit a unique sub-
set of macrophages that express triggering receptor expressed in 
myeloid cells 2 (TREM2) (29), a lipid receptor that controls metab-
olism, survival, and proliferation (12, 30). Whether these macro-
phages are beneficial or detrimental is unknown. Thus, we sought 
to examine the livers of patients with or without hepatic steatosis for 
changes in macrophage populations. Immunostaining and quanti-
tative polymerase chain reaction (qPCR) analyses showed that the 
Figure 1. NAFLD is an independent risk factor for hospital mortality in critically ill patients with sepsis. (A) Study flow diagram for identification of septic 
patients with or without NAFLD. n = 395 in non-NAFLD group, n = 129 in NAFLD group. (B) Representative CT scan illustrating measurement of patients 
with NAFLD or not. (C and D) Kaplan-Meier survival curves (28-day) (C) and hospital mortality (D) across NAFLD category. Significant difference compared 
with the non-NAFLD control was determined. n = 395 in non-NAFLD group, n = 129 in NAFLD group. (E) Adjusted hospital mortality according to age, sex, 
BMI, and site of infection. The values shown are the adjusted odds ratio (aOR, 95% confidence interval). All sepsis cases: aOR = 2.918 (1.693–5.031, P < 
0.001); male: aOR = 2.048 (0.937–4.476, P = 0.072); female: aOR = 4.366 (1.945–9.798, P < 0.001); age <65: aOR = 2.510 (1.163–5.414, P = 0.019); Age ≥65: aOR 
= 3.988 (1.766–9.006, P = 0.001); BMI <25: aOR = 3.738 (1.969–7.093, P < 0.001); BMI ≥25: aOR = 1.261 (0.431–3.696, P = 0.672); intra-abdominal: aOR = 3.725 
(1.797–7.721, P < 0.001). The data were analyzed by log-rank test (C), or Fisher’s exact test (D), or multivariate logistic regression (E). ****P < 0.0001.
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Figure 2. NAFLD patients exhibit liver mitochondria dysfunction. (A) Volcano plot showing significant DEGs (red, downregulated genes; blue, upregulat-
ed genes, Padj < 0.05) in NAFLD versus non-NAFLD livers. n = 6 in non-NAFLD group; n =5 in NAFLD group. (B) GO analysis of the identified DEGs between 
non-NAFLD and NAFLD livers. Orange (top panel) and blue (bottom panel) indicate downregulated and upregulated GO biological processes or cellular 
component in NAFLD livers, respectively. (C) Heatmap showing the expression pattern of the identified DEGs that were found to be involved in fatty acid 
metabolism, mitochondrial matrix, endoplasmic reticulum stress, apoptosis, and inflammation. The color key indicates the expression levels. (D) Repre-
sentative images of H&E-stained and ORO-stained liver sections and TEM images from non-NAFLD and NAFLD livers. H&E-stained and ORO-stained liver 
sections: n = 9 in non-NAFLD group; n = 21 in NAFLD group. TEM images: n = 7 in non-NAFLD group; n = 14 in NAFLD group. Solid and dashed white arrows 
refer to complete and fragmented mitochondria, respectively. Scale bars: 50 μm, 10 μm, and 2 μm. (E) Quantification of mitochondrial parameters from liv-
er electron microscopy images from NAFLD and non-NAFLD patients. n = 601 mitochondria from 14 NAFLD patients or 238 mitochondria from 7 controls (3 
fields/patient). (F) ATP levels in livers from non-NAFLD and NAFLD patients. n = 9 for non-NAFLD patients; n = 21 for NAFLD patients. All data are shown 
as the mean ± SD. Significance was determined by an unpaired, 2-tailed Student’s t test. ****P < 0.0001.
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of polyunsaturated fatty acids (PUFAs), including long-chain 
fatty-acid CoA ligase 4 (Acsl4), steroid hormone metabolism 
(Hsd3b5), and hepatic trefoil factor 3 (Tff3). The expression of 
lipogenesis genes (Apoa4, CD36, and Cidea) and inflammatory 
cytokine genes (Ccl2, Ly6d, Cxcl10, and TNF-α) were upregulated 
in Trem2–/– livers (Supplemental Figure 4B). These data indicate 
that Trem2 deficiency exacerbates the progression of NAFLD.
Last, we asked whether a defect of TREM2 impacted liver 
energetic metabolism and mitochondria function. Tandem mass 
spectrometry was first used to detect metabolites in both positive 
and negative ion modes in the livers of WT and Trem2–/– mice fed 
HFD for 8 weeks, after an overnight fasting. Totally, 219 and 201 
lipids and lipid-like molecules were identified in the positive and 
negative ion modes,  respectively (Supplemental Data Set 3). The 
levels of major fatty acid species, including ricinoleic acid (RA), 
linoleic acid (LA), dodecanedioic acid (DA), and arachidonic acid 
(AA), were more elevated in Trem2–/– versus WT livers (Figure 4I 
and Supplemental Figure 4C, P < 0.05). Acylcarnitine (AC) species 
ranging in size from 2 to 22 carbons were also analyzed, represent-
ing byproducts of substrate catabolism. Ions separating Trem2–/– 
and WT livers were identified as long-chain AC species (ranging 
from C14:0 to C22:0; Figure 4I, P < 0.05), suggesting insufficient 
l-carnitine shuttle of long-chain fatty acids from the cytosol to 
the mitochondria in Trem2–/– liver. In support of this, hepatic mito-
chondria in Trem2–/– mice were less uniform and more fragment-
ed compared with those in WT mice (Figure 4J). Moreover, mice 
lacking Trem2 exhibited reduced ATP levels in the liver (Figure 
4K). Together, these results suggested that Trem2–/– liver is unable 
to appropriately adjust FAO and energy metabolism due to mito-
chondrial fragmentation after HFD.
TREM2 promotes macrophage-hepatocyte metabolic coordina-
tion both in vivo and in vitro. To explore whether the aggravation 
of hepatic steatosis in HFD-fed Trem2–/– mice is due to a defect of 
liver KCs, we depleted the KCs of HFD-fed WT and Trem2–/– mice 
by administration of gadolinium chloride (GdCl3, Figure 5A, and 
ref. 32). Depletion of KCs was confirmed by a greater than 40% 
decrease in F4/80+ cells and the approximately 50% decrease in 
F4/80 mRNA expression in the liver (Supplemental Figure 5, A and 
B). Overall, compared with control mice, mice with KC depletion 
gained less body weight and had improved lipid metabolism, as 
evidenced by a decrease of serum and hepatic TG and cholesterol 
contents after 8 weeks of HFD (Figure 5, B and C, and Supplemen-
tal Figure 5C). Interestingly, in the GdCl3 group, Trem2–/– and WT 
mice showed comparable liver and serum TG and cholesterol con-
tents, liver fat accumulation, and ATP production (Figure 5, B–E). 
Together, these data support that Trem2–/– liver KCs aggravate the 
development of hepatic steatosis.
To further define the beneficial roles of TREM2 in hepatic 
steatosis in vitro, bone marrow–derived macrophages (BMDMs) 
from WT or Trem2–/– mice were cocultured with primary hepato-
cytes isolated from WT or Trem2–/– mice in trans-well plates (Fig-
ure 5F). Cultures were supplemented with palmitic acid (PA, 0.5 
mM) for 24 hours in serum-free conditions. A drastic increase 
in LDs was observed in both WT and Trem2–/– hepatocytes when 
cocultured with Trem2–/– macrophages (Figure 5G). Under these 
conditions, a luciferase-based ATP assay showed that ATP 
production decreased in hepatocytes cocultured with Trem2–/– 
HFD feeding, Trem2–/– mice gained more body weight, epididy-
mal fat pad weight, liver weight, and liver weight–to–body weight 
ratios (Figure 4, B and C; Supplemental Figure 3, A and B). Trem2 
deletion increased serum and liver triglyceride (TG) by 30%, as 
well as serum and liver cholesterol by 20% and 15%, respectively 
(Figure 4, D and E). H&E and Oil Red O (ORO) staining showed 
that Trem2–/– livers exhibited increased macrovesicular fat content, 
aggravated lipid droplet (LD) accumulation, and ballooning degen-
eration (Figure 4F). In contrast, there was no difference between 
WT and Trem2–/– mice fed a NCD (Supplemental Figure 3, C–G).
We performed unbiased transcriptome analysis of livers of WT 
versus Trem2–/– mice after feeding mice a HFD for 8 weeks (31). In 
this screen, a cluster of 104 transcripts were upregulated and 57 
were downregulated in response to Trem2 deficiency (Supplemen-
tal Data Set 2 and Supplemental Figure 4A; GSE160022). Among 
these DEGs (Padj < 0.05), gene sets that contribute to fatty acid 
metabolic dysfunction, collagen fibril organization, and cytokine 
secretion were significantly enriched in Trem2–/– livers, whereas 
those controlling long-chain/unsaturated fatty acid metabolism 
and monocarboxylic acid metabolism were overrepresented in 
WT livers (Figure 4, G and H). qPCR analysis in an independent 
cohort further confirmed that livers of HFD-fed Trem2–/– mice 
had reduced expression of genes involved in the metabolic fates 
Figure 3. TREM2+ macrophages are characteristic of livers from NAFLD 
patients. (A) Confocal images of liver sections from non-NAFLD and 
NAFLD donors show CD68 (cyan), TREM2 (red) and DAPI staining. Individ-
ual CD68+ TREM2+ macrophages are depicted at a higher magnification in 
the inserts. Confocal images at ×40 were taken with a Nikon A1 inverted 
fluorescent microscope. n = 6 in non-NAFLD group; n = 7 in NAFLD group. 
Scale bar: 20 μm. (B) qPCR analysis for liver TREM2 expression normalized 
to β-actin mRNA levels. n = 9 in non-NAFLD group; n = 21 in NAFLD group. 
All data are shown as the mean ± SD. Significance was determined by an 
unpaired, 2-tailed Student’s t test. **P < 0.01.
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macrophages compared with the hepatocytes cocultured with WT 
BMDMs (Figure 5H). These results support that TREM2 deficien-
cy impairs macrophage-hepatocyte metabolic coordination in a 
fatty acid–enriched microenvironment.
Trem2 deletion leads to changes in macrophage-Exos numbers 
and content. To explore the potential mechanism underlying FAO 
defects in livers from Trem2–/– mice fed HFD for 8 weeks, we pro-
filed KC transcriptomes isolated from these mice and their WT 
littermates by RNA-seq (Supplemental Data Set 4; GSE160022). 
Gene ontology (GO) analysis revealed that antigen processing and 
presentation, mitochondrial oxidative phosphorylation, and ATP 
synthesis were impaired in Trem2–/– KCs. However, genes linked 
to chemotaxis and inflammation (Ccr2, Cx3cr1, Spp1) were upreg-
ulated in Trem2–/– KCs (Figure 6A and Supplemental Figure 6A). 
Interestingly, genes involved in Exos secretion (Cd63, Cd9) were 
enriched in Trem2–/– KCs (Supplemental Figure 6A).
Macrophage-derived Exos can be taken up into hepatocytes to 
modulate the function of recipient cells (33). Thus, we conducted 
in vitro studies to confirm whether Trem2–/– macrophage-derived 
Exos were the underlying mechanism of Trem2–/– liver FAO defects 
and ATP deficiency. BMDMs with different genotypes were stim-
ulated with PA (0.5 mM) or control vehicle for 12 hours. After 
removal of dead cells and debris from the conditioned medium, 
extracellular vesicles (EVs) were isolated by differential ultracen-
trifugation. These EVs were confirmed to primarily consist of Exos, 
as evidenced by the expression of the Exos-specific protein mark-
ers CD63, CD81, and Alix, but not cytochrome C (mitochondria), 
GM-130 (Golgi), or calnexin (ER) proteins (Supplemental Figure 
6B). TEM (Figure 6B) and NanoSight analysis (Figure 6C) corrob-
orated that the particles were BMDM-derived Exos (BMDM-Exos) 
with a diameter of 30–150 nm. The overall Exos number isolated 
from the same amount of medium from the Trem2–/– BMDMs group 
was much higher than that from WT BMDMs group (Figure 6C).
Next, we incubated the WT primary hepatocytes with equal 
amounts of WT or Trem2–/– BMDM-Exos (20 μg/mL) for 12 hours 
under PA (0.5 mM) stimulation. Compared with WT BMDM-Exos–
treated hepatocytes, hepatocytes incubated with Trem2–/– BMDM-
Exos showed a significant increase in LD accumulation (Figure 6D), 
suggesting that the composition of WT BMDM-Exos and Trem2–/– 
BMDM-Exos diverges under a fatty acid–rich environment. Further, 
to replicate the in vitro phenomenon in vivo, WT mice fed a HFD 
for 7 weeks were used as recipients and intravenously injected with 
PKH26-labeled WT or Trem2–/– BMDM-Exos for 3 weeks (30 μg 
every 7 days, Figure 6E). The appearance of red fluorescent PKH26 
dye in the livers of recipient mice indicated the in vivo uptake of 
Exos in the liver (Supplemental Figure 6C). Compared with the WT 
BMDM-Exos group, Trem2–/– BMDM-Exos–injected mice gained 
more liver weight and liver weight–to–body weight ratios, while 
the body weight and epididymal fat pad weights were compara-
ble between the 2 groups (Figure 6F and Supplemental Figure 6, 
D and E). Trem2–/– BMDM-Exos–injected mice showed increased 
serum and liver TG content and hepatic LD accumulation (Figure 
6, G–I). ATP production was lower in the livers of Trem2–/– BMDM-
Exos–injected mice compared with WT BMDM-Exos–injected mice 
(Figure 6J). Therefore, our data show that liver macrophage TREM2 
attenuates NAFLD progression in an Exos-dependent manner.
Macrophage-derived Exos impair hepatocyte mitochondria due to 
high content of miR-106b-5p that blocks Mfn2. miRNAs are regula-
tory molecules that can be packaged into Exos and secreted from 
cells (33–35). To assess the NAFLD-induced changes in expres-
sion of KCs miRNAs, we conducted deep sequencing of small 
RNAs from KCs isolated from WT and Trem2–/– mice fed HFD for 
8 weeks. More than 1000 miRNAs were identified in KCs (Supple-
mental Data Set 5; GSE160022). A set of miRNAs were upregu-
lated in Trem2–/– versus WT KCs, among which miR-106b-5p was 
the most abundant miRNA in KCs (Figure 7A, Supplemental Data 
Set 5, and ref. 36). In an independent cohort, our results confirmed 
that KCs from Trem2–/– mice expressed greater intracellular levels 
of miR-106b-5p after 8 weeks of HFD feeding (Supplemental Fig-
ure 7A), which led to increased levels of miR-106b-5p present in 
the livers (Supplemental Figure 7B). Consistent with these in vivo 
results, the miR-106b-5p abundance was significantly increased in 
Trem2–/– BMDM-Exos (~6-fold) after treatment with PA (0.5 mM) 
for 12 hours (Supplemental Figure 7C).
To evaluate the role of miR-106b-5p on lipid metabolism, we 
transfected BMDMs with Cy3-labeled miR-106b-5p mimic or 
negative control (NC) via lipofectamine RNAiMAX (Supplemen-
tal Figure 7, D and E). After 12 hours of coculture with miR-106b-
5p mimic–transfected BMDMs, the hepatocyte exhibited efficient 
uptake of the macrophage-secreted miR-106b-5p (~80% efficien-
cy), as indicated by the presence of red fluorescence (Supplemen-
tal Figure 7D) and increased miR-106b-5p abundance within the 
hepatocytes (Supplemental Figure 7F). The increased miR-106b-
5p abundance in hepatocytes led to a significant increase in LD 
accumulation after PA treatment for 12 hours in serum-free con-
ditions, accompanied by decreased ATP production within the 
hepatocytes (Figure 7, B and C).
miR-106b-5p was previously reported to target Mfn2 (37). Mfn2 
plays a crucial role in controlling mitochondrial fusion, which is 
required for oxidative phosphorylation, mitochondrial DNA bio-
genesis, mitophagy regulation, and metabolic adaptation (38). 
Since Mfn2 ablation in the liver was shown to cause a NASH-like 
Figure 4. Trem2 deficiency exacerbates hepatocyte mitochondrial dysfunc-
tion and accelerates NAFLD progression in a mouse model. (A) Experimental 
design used to evaluate the role of Trem2 in NAFLD progression. Liver weights 
(B) and liver weight/body weight ratios (C) of WT and Trem2–/– mice after being 
fed HFD for 8 weeks. n = 10 in WT group; n = 13 in Trem2–/– group. Levels of 
TG (D) and cholesterol (E) in serum and livers from mice after being fed HFD 
for 8 weeks. n = 6 in WT group; n = 9 in Trem2–/– group. (F) Representative 
images of H&E- and ORO-stained liver sections. n = 4 in WT group; n = 4-5 
in Trem2–/– group. Solid and dashed black arrows indicate hepatocytes with 
macrovesicular fat (Macroves. fat) or hepatocyte ballooning (Hep. balloon.), 
respectively. Number of hepatocytes with Macroves. fat or Hep. balloon. and 
percentage of ORO-positive area per high magnification field (HMF) was deter-
mined by ImageJ from 6 fields per section. Scale bar: 100 μm. (G) GO analysis 
of the identified DEGs between WT and Trem2–/– groups (n = 3 per group). (H) 
Heatmap showing the expression pattern of the identified DEGs (n = 3 per 
group). The color key indicates the expression levels. (I) Heatmap displays the 
upregulated and downregulated lipid species in livers (n = 9 mice per group), P 
< 0.05. The color key indicates the lipid levels. (J) Representative TEM images 
of mouse hepatocytes (upper) and hepatocellular mitochondria (bottom). n = 
4 in WT group; n = 5 in Trem2–/– group. Solid and dashed white arrows refer to 
complete and fragmented mitochondria, respectively. Scale bars: 10 μm and 1 
μm, respectively. (K) ATP levels in WT and Trem2–/– livers. n = 7 per group. All 
data are shown as the mean ± SD. The data were analyzed by an unpaired, 
2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 5. Macrophage Trem2 deficiency exacerbates hepatocyte lipid accumulation both in vivo and in vitro. (A) Schematic representation of the timing 
strategy used to evaluate the role of KCs in NAFLD progression. n = 12 in WT CTRL group; n =5 in Trem2–/– CTRL group; n =10 in WT GdCl3 group; n =5 in 
Trem2–/– GdCl3 group. (B and C) Serum and liver triglyceride or cholesterol levels in response to KCs depletion. (D) Representative images of H&E- and ORO-
stained liver sections. H&E reveals tissue composition and macrovesicular fat, and ORO visualizes lipid droplets. Number of hepatocytes with macrove-
sicular fat and percentage of ORO-positive area per HMF was determined by ImageJ from 6 fields per section. Scale bar: 100 μm. (E) ATP contents in the 
liver. (F and G) Representative image of ORO-stained hepatocytes after coculture with BMDMs (F). BMDMs from WT or Trem2–/– mice were cocultured with 
primary hepatocytes isolated from WT or Trem2–/– mice in transwell plates. Cultures were added with PA (0.5 mM) for 24 hours in serum-free conditions. 
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Trem2–/– mice showed comparable survival and organ injury to the 
NCD-fed WT mice (Supplemental Figure 8, D–F), corroborating that 
TREM2 deficiency increases the susceptibility to septic insult only 
in the presence of a liver metabolic disorder caused by HFD. Taken 
together, our results support the notion that liver metabolic failure 
and severe liver dysfunction are important causes of septic death in 
HFD-fed Trem2–/– mice. We do not exclude that defects in the Trem2–/– 
macrophages of other organs may also contribute to septic death.
Elevated TREM2 gene dosage in liver macrophages suppress-
es steatohepatitis and relieves sepsis-induced organ dysfunction. To 
further corroborate that macrophage TREM2 alleviates altered 
hepatic energetic metabolism and subsequent liver dysfunction 
in NAFLD-associated sepsis, we tested whether increasing the 
macrophage TREM2 gene dosage could modify disease patho-
genesis. We generated a transgenic mouse line expressing the 
common variant of human TREM2 (BAC-TREM2) in addition to 
WT endogenous TREM2. Because human and mouse TREM2 are 
highly homologous and have evolutionarily conserved functions, 
BAC-TREM2 mice provide a model of TREM2 overexpression (41, 
42). BAC-TREM2 and WT littermates were placed on HFD for 10 
weeks (Figure 9A). To verify cell type–specific expression of human 
TREM2 transgene in livers of mice fed HFD for 10 weeks, we per-
formed immunofluorescence microscopy of liver sections using 
an antibody against the C terminus of human TREM2. Human 
TREM2 colocalized exclusively with the macrophage marker 
Iba1 (Supplemental Figure 9A). In parallel, real-time qPCR data 
showed BAC-TREM2 mice expressed murine Trem2 transcripts at 
levels comparable to WT mice after 10 weeks of HFD (Supplemen-
tal Figure 9B). Upon HFD feeding, BAC-TREM2 mice featured 
decelerated body/liver weight gain (Figure 9, B and C and Supple-
mental Figure 9C). No difference was detected in white adipose 
tissue weight between the BAC-TREM2 mice and WT littermates 
(Supplemental Figure 9D). H&E and ORO analysis of liver sec-
tions showed that BAC-TREM2 mice had alleviated macrovesic-
ular fat content, ballooning degeneration and lobular inflamma-
tion, and less LD accumulation after 10 weeks of HFD (Figure 9, 
D–F). Consistently, BAC-TREM2 mice showed improved hepatic 
FAO after overnight fasting, as evidenced by decreased hepatic 
TG content and increased ATP production (Figure 9, G and H).
To determine whether the elevated macrophage TREM2 dos-
age could impact susceptibility of NAFLD mice to polymicrobial 
sepsis-induced liver injury, sepsis was induced by mild CLP and 
mice were monitored for organ injuries, systemic bacteria burden, 
and cytokine production. Liver injury and lung injury were alle-
viated in the BAC-TREM2 group compared with WT littermates, 
accompanied by low blood bacteria burden and improved hepatic 
ATP production (Figure 9, I–K). There was no difference in sys-
temic cytokine production, except for a trend in MCP-1 reduction 
in the BAC-TREM2 group (Supplemental Figure 9E). Overall, our 
data suggest that TREM2 overexpression in liver macrophages 
plays a protective role in defense against NAFLD-associated sep-
sis by facilitating liver switch to FAO metabolism.
Discussion
The liver is a prime target in sepsis-related injury, especially in the 
context of preexisting hepatic impairment (43). Here, we performed 
a clinical cohort study and showed that NAFLD is an independent 
phenotype and liver cancer (39, 40), we examined whether the 
upregulated miR-106b-5p downregulates Mfn2 protein levels and 
causes mitochondrial dysfunction in our model. BNL.CL2 hepato-
cytes were transfected with the indicated miR-106b-5p mimic 
or NC and examined by immunoblotting. As shown in Figure 7D, 
overexpression of miR-106b-5p markedly downregulated Mfn2 
protein levels in hepatocytes. Taken together, Trem2–/– macrophages 
exacerbate hepatocyte FAO dysfunction by promoting macrophage 
release of Exos that impair hepatocyte mitochondrial homeostasis 
through their content of miR-106b-5p, which blocks Mfn2.
Trem2 deficiency increases the susceptibility to NAFLD-associated 
 sepsis in vivo. To further assess the involvement of TREM2 in the 
susceptibility of NAFLD mice to sepsis, we performed a survival 
study on WT and Trem2–/– mice fed a NCD or HFD for 8 weeks. 
After dietary intervention, lethal polymicrobial sepsis was induced 
by cecal ligation and puncture (CLP), and mice were monitored 
for 3-day survival (Figure 8A). We found that all of the HFD-fed 
mice (WT and Trem2–/–) died within 3 days following the surgery, 
whereas less than 40% of NCD-fed mice (WT and Trem2–/–) died 
within the 3-day study period (Figure 8B). Compared with WT 
NAFLD mice, Trem2–/– NAFLD mice had a shorter survival time 
following induction of lethal sepsis (Figure 8B).
To explore the factors that exacerbate septic mortality, sys-
temic bacterial burden and cytokines were measured. Com-
pared with HFD-fed WT mice, the systemic bacteria burden was 
increased in HFD-fed Trem2–/– mice after sepsis insult; however, 
there was no difference between the NCD-fed Trem2–/– mice and 
HFD-fed Trem2–/– mice (Figure 8C). Additionally, there was no sig-
nificant difference in cytokine production among different mouse 
genotypes either with NCD or HFD treatment (Figure 8D). Given 
the difference in the survival between the HFD-fed Trem2–/– group 
and the other 3 groups, our data suggested that factors other than 
bacterial burden and proinflammatory cytokines worsen the sep-
sis outcome in HFD-fed Trem2–/– mice.
Furthermore, TEM showed more severe mitochondrial frag-
mentation in Trem2–/– livers than in WT livers, accompanied by a 
significant decrease in ATP production (Figure 8, E and F), indi-
cating that the fragility of HFD Trem2–/– liver may be an import-
ant risk factor in sepsis insult. In support of this possibility, more 
severe liver injury and lung injury were observed in Trem2–/– than 
that in WT mice on day 1 after CLP insult, as evaluated by bleeding 
and inflammatory cell infiltration (Supplemental Figure 8A). The 
plasma ALT concentration of HFD-fed Trem2–/– mice was approx-
imately double that in HFD-fed WT mice (Supplemental Figure 
8B). In addition, there was about 50% decrease in plasma albumin 
concentration in the HFD-fed Trem2–/– mice (Supplemental Figure 
8C), indicating that liver failure occurred in HFD-fed Trem2–/–mice.
An additional LPS-induced sepsis model (10 mg/kg LPS) was 
performed in NCD-fed Trem2–/– and WT littermates. NCD-fed 
Lipid accumulation in hepatocytes was determined by quantification of 
ORO-positive area as a percentage of whole image area by ImageJ (G). n = 9 
per group. Scale bar: 50 μm. (H) ATP content in hepatocytes was quanti-
fied by luciferase assay. n = 9 per group. The data were analyzed by 1-way 
analysis of variance with Bonferroni corrections for multiple comparisons. 
All data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001.
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Figure 6. Trem2 deletion changes macrophage-Exos numbers and contents. (A) GO analysis of DEGs in KCs from WT or Trem2–/– mice fed HFD for 8 weeks. 
n = 3 per group. (B) Representative TEM images of Exos from WT and Trem2–/– BMDMs incubated with PA (0.5 mM) for 12 hours. Scale bar: 100 nm. (C) 
Representative results of nanoparticle tracking analysis demonstrate size distribution of Exos derived from WT and Trem2–/– BMDMs. n = 5 per group. (D) 
WT primary hepatocytes were incubated with WT or Trem2–/– BMDM-derived Exos (20 μg/mL) and PA (0.5 mM) for 12 hours. Lipid accumulation in hepato-
cytes was determined by quantification of ORO-positive area as a percentage of whole image area by ImageJ. n = 16 in WT group; n = 19 in Trem2–/– group. 
Scale bar: 25 μm. (E) Experimental design used to evaluate BMDM-Exos in NAFLD progression. n = 6 in WT-Exos group; n = 5 in Trem2–/–-Exos group. (F) 
Liver weights and liver weight/body weight ratios of mice with Exos treatment. (G and H) Serum and liver triglyceride levels in response to Exos treat-
ment. (I) Representative images of ORO-stained liver sections from mice treated with Exos from WT or Trem2–/– BMDMs. Scale bar: 100 μm. Percentage of 
ORO-positive area per HMF were determined by ImageJ from 6 fields per section. (J) ATP content in hepatocytes was quantified by luciferase assay. Data 
are presented as the mean ± SD. The data were analyzed by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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that NAFLD was paralleled by the expansion of liver macrophages 
expressing TREM2, which impacted hepatic mitochondrial dys-
function. Trem2-deficient macrophages released Exos that impaired 
hepatocytic mitochondrial structure and energy supply because of 
their high content of miR-106b-5p, which blocks Mfn2. Trem2 dele-
tion exacerbated NAFLD as well as susceptibility of mice to sepsis. 
Conversely, overexpression of TREM2 in liver macrophages atten-
uated steatohepatitis and sepsis-induced mortality. Collectively, 
these findings support hepatic mitochondrial dysfunction as a signif-
icant mediator of the pathogenesis of NAFLD and NAFLD-associ-
ated sepsis, and demonstrate a role for macrophage TREM2 in pro-
tecting hepatocytes against mitochondrial dysfunction (Figure 10).
Frequently, septic patients exhibit chronic diseases such as 
NAFLD, which is the most common chronic liver disease (4, 5). In 
our current prospective clinical cohort study, 24.62% patients with 
sepsis were identified as NAFLD. The NAFLD cohort showed sig-
nificantly increased 28-day mortality and hospital mortality com-
pared with the non-NAFLD cohort. Moreover, within the NAFLD 
cohort, female patients and patients aged 65 and over had a pre-
dominantly higher risk for adverse clinical outcomes following sep-
sis than patients in the other cohorts, probably due to the high rate 
of comorbidities in those patients. Diabetes is known to strongly 
associate with NAFLD, but whether this may lead to adverse clin-
ical outcomes was unknown (20). We found that both the 28-day 
mortality and hospital mortality in the NAFLD group were still sig-
nificantly higher than the non-NAFLD group after excluding these 
diabetic patients. The same tendency was also observed in diabetic 
patients. Moreover, in the NAFLD group, the mortality in patients 
with and without diabetes was comparable, indicating a strong 
link between NAFLD and septic mortality. Since sepsis is associ-
ated with a shift from glycolysis to FAO for energy supply in the 
liver (22), lipid overload and excess of toxic fatty acids in NAFLD 
may impair mitochondrial FAO, affecting liver function and, con-
sequently, energy supply to other vital organs during sepsis. Thus, 
targeting hepatic FAO and energy metabolism may improve the 
outcome of septic patients with NAFLD.
A recent study identified the emergence of Trem2+ NASH- 
associated KCs as a feature of mouse and human NASH (29). In 
our study, liver immunostaining also revealed increased numbers 
of CD68+TREM2+ and F4/80+TREM2+ KCs in NAFLD donors and 
HFD-fed mice, respectively. Since it was shown that monocytes can 
acquire a KC profile once they reach the space of Disse (44), wheth-
er TREM2+ KCs in NAFLD livers are bona fide KCs or derive from 
the infiltration and differentiation of monocytes remains unclear. 
TREM2 was recently shown to control lipid metabolism in microg-
lia and adipose tissue macrophages (12, 13, 30). Our study extends 
these findings, showing that deletion of Trem2 in a mouse NAFLD 
model increased hepatocyte lipid content and accumulation of fatty 
acid species, reduced long-chain acylcarnitine species and ATP pro-
duction, and augmented mitochondria fragmentation. Moreover, 
Trem2–/– NAFLD mice showed worse outcomes than WT NAFLD 
mice following polymicrobial sepsis, whereas overexpression of 
TREM2 on KCs alleviated NAFLD and adverse septic outcome. 
While the impact of TREM2 on sepsis outcome may be due to its 
influence on hepatocyte energy supply, FAO, and mitochondrial 
function, we cannot exclude additional contributions of TREM2 to 
other macrophage compartments involved in immune responses. 
risk factor for hospital mortality after adjusting for age, sex, BMI, 
and site of infection. Liver transcriptome analysis and liver biopsies 
showed that mortality in NAFLD-associated sepsis was associat-
ed with impaired lipid metabolism, severe hepatic mitochondrial 
fragmentation, and decreased ATP content. Remarkably, we found 
Figure 7. Trem2 deletion impacts macrophage-Exos miRNA profiles. (A) 
Heatmap of small RNA transcripts in WT and Trem2–/– KCs after 8-week 
HFD and sequence alignment of miR-106b-5p with 3′ UTRs of mouse 
(Mmu), human (Hsa), and rat (Rno) Mfn2. n = 4 for each group. The color 
key indicates the expression levels. (B and C) WT BMDMs were transfected 
with either NC or miR-106b-5p mimic and then cocultured with primary WT 
hepatocytes in a transwell plate for 12 hours with 0.5 mM PA stimulation. 
Lipid accumulation in hepatocytes was determined by quantification of 
ORO-positive area as a percentage of whole image area by ImageJ (B), n = 
9 per group. Scale bar: 25 μm. ATP content in hepatocytes was quantified 
by luciferase assay (C), n = 6 per group. (D) Representative Western blot 
images of Mfn2 expression in BNL CL.2 cells, which were transfected with 
either NC or miR-106b-5p mimic and then stimulated with 0.5 mM PA for 
6 hours. The integrated density of the blots was analyzed by ImageJ. n = 3 
per group. Data are presented as the mean ± SD. Data were analyzed by an 
unpaired, 2-tailed Student’s t test. *P < 0.05, ****P < 0.0001. 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(4):e135197  https://doi.org/10.1172/JCI1351971 2
In conclusion, by examining a large cohort of patients with 
NAFLD and sepsis, we defined the contribution of NAFLD to sepsis 
mortality. Our findings underscore the importance of mitochon-
drial metabolic dysfunction in the pathogenesis of NAFLD-associ-
ated sepsis, show that metabolic coordination between liver mac-
rophages and hepatocytes protects from NAFLD, demonstrate the 
requirement for TREM2 for such coordination, and highlight the 
TREM2 pathway as a potential avenue of therapeutic intervention 
for NAFLD-associated sepsis.
Methods
Study design, setting, and population. Patients who met the Sepsis 3.0 
clinical criteria were screened for eligibility within the first 24 hours 
after they were admitted to the intensive care unit (ICU) of Zhejiang 
University Hospital between September 2012 and January 2019 (1, 45). 
Information was extracted from a prospectively designed database. 
A total of 524 patients who had CT of the abdomen within 2 months 
prior to ICU admission or during ICU stay were enrolled. Exclusion 
criteria were age younger than 18 years or older than 80 years, with 
liver cirrhosis, with alcohol consumption (>140 g/week in men or >70 
g/week in women), with a previous positive test for hepatitis B surface 
The critical role of macrophage TREM2 in attenuating lipid 
accumulation in hepatocytes in the NAFLD model was corroborat-
ed by an in vivo KC depletion model and in vitro coculture system. 
Since TREM2 is expressed in macrophages but not hepatocytes, 
how could TREM2 in liver KCs control lipid metabolism in hepato-
cytes? We found that the role of macrophage TREM2 in hepatic lipid 
handling and catabolism was related to the Exos pathway: Trem2–/– 
macrophages released more Exos than WT macrophages, and Exos 
were taken up by neighboring hepatocytes modulating their func-
tion through miRNAs (33). Among several miRNAs, we focused on 
miR-106b-5p because it was enriched in KCs, was upregulated in 
obese adipose tissue macrophage–derived Exos (33, 36), and was 
shown to target the mitochondrial membrane protein Mfn2, which 
is important for mitochondria function (37, 39). In a transwell assay, 
Cy3-labeled miR-106b-5p transfected in macrophages was readily 
detected in hepatocytes with hundreds of fold increase in expres-
sion. This increase in hepatocyte abundance of miR-106b-5p led to 
a significant increase in lipid droplet accumulation after PA treat-
ment, accompanied by decreased ATP production and Mfn2 down-
regulation. Understanding how TREM2 controls Exos secretion and 
miR-106b-5p expression will require additional studies.
Figure 8. Trem2 deficiency increases susceptibility to NAFLD-associated sepsis. (A) Experimental design used to set up NAFLD and sepsis. (B) WT and 
Trem2–/– mice fed NCD or HFD for 8 weeks were subjected to lethal CLP with an 18-gauge needle, and mice survival was monitored every 12 hours. n = 10 for 
NCD WT mice; n = 11 for NCD Trem2–/– mice; n = 11 for HFD WT mice; n = 13 for HFD Trem2–/– mice. (C) Blood bacterial burden at 24 hours post-CLP. n = 5 for NCD 
WT mice; n = 6 for NCD Trem2–/– mice; n = 4 for HFD WT mice; n = 6 for HFD Trem2–/– mice. (D) Plasma cytokine markers were quantified 24 hours after CLP.  
n = 5 per group. (E) Representative TEM images of mouse hepatocellular mitochondria obtained from WT or Trem2–/– mice livers 24 hours after CLP. n = 2–6 for 
each group. Scale bar: 1 μm. (F) Levels of ATP contents in livers from WT or Trem2–/– mice at 24 hours after CLP. n = 7 in WT NCD group; n = 8 in Trem2–/– NCD 
group; n = 6 in WT HFD group; n = 9 in Trem2–/– HFD group. Data are presented as the mean ± SD. Data were analyzed by 1-way analysis of variance with Bon-
ferroni corrections for multiple comparisons (C, D, and F). The survival rates were analyzed by log-rank test (B). *P < 0.05, **P < 0.01, ***P < 0.001. 
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Liver tissues. Liver samples from NAFLD or apparently healthy 
patients were obtained from donors who underwent organ dona-
tion after cardiac death (DCD) with proper ethical approvals from 
institutional review boards. The exclusion criteria was the same 
as mentioned above. The NAFLD activity was evaluated by biop-
sies at cold ischemia in all graft livers. The grade of liver steatosis 
was determined according to international standards (46). Score 
0 (non-NAFLD) indicates steatosis area < 5%; score 1–3 (NAFLD) 
antigen or hepatitis C antibody, and treatment with medications that 
can cause hepatic steatosis. Based on the LA value ≤ 40 HU criteria 
(hepatic steatosis area >30%, moderate-to-severe, refs. 16–19), 129 
septic patients with NAFLD were identified. Clinical characteristics 
of 524 adults with sepsis according to hepatic steatosis categories 
are summarized in Supplemental Table 1. The study protocol was 
approved by the local institutional review board, and written informed 
consent was obtained from all subjects or their surrogates.
Figure 9. Increase in TREM2 gene dosage reduces steatohepatitis and sepsis-induced liver injury. (A) Experimental design used to evaluate the role of 
elevated TREM2 gene dosage in NAFLD progression and sepsis. (B and C) Body weight (B) and liver weight (C) of BAC-TREM2 and littermate WT control 
mice after a 10-week HFD. n = 11 in WT group; n = 15 in BAC-TREM2 group. Filled and open symbols refer to male and female, respectively. (D–F) Repre-
sentative images of H&E-stained and ORO-stained liver sections (D). H&E revealed tissue composition, macrovesicular fat, hepatocyte ballooning, and 
lobular inflammation. ORO visualized lipid droplets. Number of hepatocytes with macrovesicular fat or hepatocyte ballooning, lobular inflammation score, 
and percentage of ORO-positive area per HMF was determined by ImageJ from 5 fields per section (E and F). n = 7 in WT group; n = 11 in BAC-TREM2 group. 
Scale bar: 100 μm. (G and H) Levels of hepatic triglyceride (G) and ATP (H) from BAC-TREM2 and littermate WT mice after a 10-week HFD. n = 7 in WT 
group; n = 11 in BAC-TREM2 group. (I and J) Organ injury and bacteria burden at 24 hours after CLP. Male BAC-TREM2 and WT mice were fed with HFD for 
10 weeks. After dietary intervention, mild polymicrobial sepsis was induced by CLP (24-gauge needle). At 24 hours after CLP, livers, lungs, and blood were 
collected for H&E staining (I) and bacterial burden test (J), respectively. n = 6 in WT group; n = 5 in BAC-TREM2 group. Scale bar: 100 μm. (K) Hepatic ATP 
levels were quantified by luciferase assay. n = 6 in WT group; n = 5 in BAC-TREM2 group. Data are represented as the mean ± SD. Significance was deter-
mined by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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from WT or Trem2–/– mice fed HFD for 8 weeks, a small RNA library 
was generated using the Illumina Truseq Small RNA Preparation kit 
following the manufacturer’s guidelines. miRNA-seq reads were sub-
jected to ACGT101-miR (LC Sciences) to sequence the data. Subse-
quently, unique sequences with length around 18–26 nucleotides were 
then mapped to all mouse miRNA hairpin sequences in miRBase 22.0 
to identify known miRNAs and novel 3p- and 5p-derived miRNAs 
(49). Differential expression of miRNAs based on normalized deep- 
sequencing counts was analyzed by selectively using a Student’s t test. 
The significance threshold was set to 0.05 in each test. Sequencing data 
supporting these studies can be found at the Gene Expression Omnibus 
database under accession number GSE160022.
Kupffer cell depletion. Animals received 2 intravenous injections 
of sterile GdCl3 (20 mg/kg; Millipore Sigma, G7532) or vehicle con-
trol per week during the HFD feeding. After 8 weeks of dietary expo-
sure, animals were fasted overnight before the tissues (blood, liver, 
adipose tissue) were harvested (32).
Cecal ligation and puncture model. Cecal ligation and puncture 
(CLP) was performed as described previously (45, 50). Briefly, mice 
were anesthetized with an i.p. injection of ketamine/xylazine (100 
mg/kg and 10 mg/kg). After a 1.5 cm abdominal incision, the cecum 
was externalized, ligated (75%) with 4:0 silk sutures, and punctured 
once with an 18-gauge needle (lethal) or 24-gauge needle (mild/less 
catastrophic) by one through-and-through puncture. We then inter-
nalized the cecum, closed the incision with 4:0 sutures, and resusci-
tated mice with 1 mL subcutaneous sterile saline. For survival exper-
iments, mice were observed for mortality every 12 hours. In some 
experiments, mice were sacrificed at 24 hours post-CLP surgery, and 
then blood and organs were harvested.
Exosome purification and characterization. Exosomes were isolat-
ed by differential ultra-centrifugation as described previously (6, 33). 
BMDMs with different genotype were stimulated with 0.5 mM PA 
(Millipore Sigma, P0500) or control vehicle for 12 hours in exosome 
free medium. Dead cells and debris in culture media (depleted from 
serum-exosomes) were first removed by centrifuging at 350g for 5 
minutes, and then the supernatant underwent a second centrifugation 
indicates steatosis area ≥ 5%. All microscopic H&E-stained sections 
and ORO-stained sections were evaluated by 2 pathologists in a dou-
ble-blinded fashion. Nine non-NAFLD donors and 21 NAFLD donors 
were included. NAFLD activity and liver function of the 30 donors 
are summarized in Supplemental Table 2.
Mice. All animal experiments were reviewed and approved by 
the Animal Advisory Committee at Zhejiang University and Wash-
ington University in St. Louis for the care and use of laboratory ani-
mals. Trem2-deficient (Trem2–/–) mice on C57BL/6 background or 
BAC transgenic mice on C57BL/6 background and their littermate 
WT controls were generated as previously described (12, 41). All the 
mice were bred and maintained in a specific pathogen–free facility in 
standard cages at 22°C to 24°C with a 12 hour light-dark cycle. Eight-
week-old mice were fed a normal control diet (NCD) (18.3% protein, 
10.2% fat, and 71.5% carbohydrates; Research Diets, D12450B) or 
a high fat diet (HFD) (18.1% protein, 61.6% fat, and 20.3% carbo-
hydrates; Research Diets, D12492) ad libitum for another 8 or 10 
weeks. All fodder was replaced weekly to avoid contamination. For 
characterization of liver under HFD or NCD conditions in different 
genotype mice, all mice were fasted overnight prior to harvest.
RNA sequencing and differential expression analysis. Human/mouse 
liver samples or isolated mouse KCs from mice fed HFD for 8 weeks 
were subjected to parallel RNA sequencing using Illumina Hiseq plat-
form (Novogene Experimental Department). Differential expression 
analysis was performed using the DESeq2 R package (1.16.1) (47). Read 
counts were used as input and normalized using built-in algorithms in 
DESeq2. Pairwise comparisons among the 2 conditions/groups were 
done on all genes. The resulting P values were adjusted using the Ben-
jamini and Hochberg’s approach for controlling the false discovery 
rate. Genes with an adjusted P value less than 0.05 found by DESeq2 
were assigned as differentially expressed. GO enrichment analysis of 
DEGs was implemented by the cluster Profiler R package, in which 
gene length bias was corrected (48). GO terms with corrected P value 
less than 0.05 were considered significantly enriched by DEGs.
MicroRNA sequencing (miRNA-seq) was profiled by the small 
RNA sequencing analysis (Illumina). Using the KCs RNA-isolated 
Figure 10. Schematic illustration of a mechanism 
through which macrophage TREM2 protects against 
NAFLD associated sepsis. Under a free fatty acid–
enriched (FFA-enriched) environment, macrophage 
TREM2 restrains the release of exosomes contain-
ing miR-106b-5p that targets to Mfn2 and leads to 
mitochondrial fragmentation in liver cells. The severely 
impaired energy supply in the Trem2–/– liver enhances 
susceptibility to sepsis. Strategies that target mac-
rophage TREM2 may be an effective way to suppress 
steatohepatitis and relieve sepsis-induced liver dys-
function and multiple organ dysfunction syndrome.
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ethanol series, and embedded in epoxy resin. The tissue was sliced 
using an ultra-microtome (Leica EM UC7). Ultrathin sections (100 
nm) were mounted on copper grids and contrasted with 4% uranyl 
acetate and lead citrate. For exosome characters, exosomes resus-
pended in PBS as described above were pipetted onto 200 μm mesh 
formvar/carbon grids (EMS) which had been glow-discharged for 15 
seconds. Samples were incubated on grids for 30 seconds and subse-
quently negatively stained with a 2% uranyl acetate solution. Grids 
were observed with TEM (Tecnai G2 Spirit 120kV, Thermo Fisher 
Scientific) at the Center of Cyro-Electron Microscopy, Zhejiang Uni-
versity. The images for hepatocyte and exosomes were taken inde-
pendently. Quantification of mitochondrial parameters in hepatocytes 
was performed using ImageJ (length, diameter, and area; ref. 52). The 
percentage of damaged mitochondria was calculated. All quantifica-
tions were performed in double-bind fashion.
RNA isolation and detection of miRNA and mRNA. Total RNA was 
isolated either from tissue samples or cultured cells using TRIzol 
reagent (Thermo Fisher Scientific, 15596-026). The obtained total 
RNA was then reverse-transcribed into cDNA using the Reverse 
Transcription System (Promega, A3500) or the Mir-X miRNA first-
strand synthesis kit (Takara, 638313) according to the manufacturer’s 
instructions. TB Green premix Ex Taq II (Takara, RR820A) was used 
to quantify the PCR amplification products. The mRNA expression 
levels of the target genes were normalized to β-actin/GAPDH expres-
sion (Supplemental Table 3) and the miR-106b-5p expression levels 
were normalized to U6 (GeneCopoeia; mmu-miR-106b-5p primer: 
HmiRQP0029; U6 primer: HmiRQP9001). For exosome miRNA 
samples, 5 pg cel-miR-39 mimic (Qiagen, 219610) was added as an 
external control before isolated. The 2−ΔΔCt method was used to calcu-
late relative gene expression levels.
Liver macrophage sorting and analysis. Liver macrophage sorting 
was performed using BD FACS Aria II flow cytometer (BD Bioscienc-
es). In brief, livers from HFD-fed mice were digested with collagenase 
type-I and DNase at 37°C after a low-pressure intraportal perfusion 
with EDTA and dispose solution. Cell suspension was filtered through 
Nylon gauze mesh, and centrifuged at 1000g for 10 minutes. Then, 
single cells were isolated by using lymphocyte separation medium 
(DAKEWE, 7211011). After washed by PBS, liver nonparenchymal cells 
(NPCs) were stained by anti-mouse F4/80 (BM8, rat monoclonal, 1:50; 
Thermo Fisher Scientific, 12-4801-82) and anti-mouse CD11b (M1/70, 
rat monoclonal, 1:50; BD Biosciences, 553312) for 20 minutes while 
protected from light. Monocyte-derived macrophages (F4/80+CD-
11bhi) and KCs (F4/80hiCD11b+) were acquired on the sorting flow 
cytometer and analyzed using FlowJo version 10 software (Tree Star).
Statistics. All data are presented as mean ± SD. Calculation for 
statistical significance was measured using 2-tailed Student’s t test 
or 1-way analysis of variance with Bonferroni corrections or Fisher’s 
exact test as indicated in figure legends. Survival rates were analyzed 
using the log-rank test. Logistic regression analysis was used to exam-
ine covariate-adjusted associations between NAFLD and hospital 
mortality. Numbers of cohorts and n values for each experiment are 
indicated in figure legends. All statistical analyses were performed 
using Prism 8.0 software (GraphPad Software Inc.), and P values less 
than 0.05 were considered statistically significant.
Study approval. Human study protocols were approved by the insti-
tutional review board of Zhejiang University and written informed con-
sent was obtained from all subjects or their surrogates. All animals were 
at 2000g for 20 minutes and a third centrifugation at 16,500g for 30 
minutes. The supernatant was then subjected to ultracentrifugation at 
110,000g for 2 hours. After washing with sterile PBS and being recentri-
fuged at 110,000g for 2 hours, the exosome-containing pellet was resus-
pended by PBS. Protein concentration was determined by bicinchoninic 
acid assay (Thermo Fisher Scientific, 23227). Further, exosome size 
distribution was measured by nanoparticle tracking analysis using 
the NanoSight LM10 (Malvern Panalytical). The device measures the 
Brownian motion of particles whose speed of motion, or diffusion coef-
ficient, is related to particle size through the Stokes-Einstein equation.
Exosome in vivo treatment. Exosomes (30 μg) derived from PA-treat-
ed (0.5 mM, 12 hours) BMDMs were rapidly injected into WT mice via tail 
vein with a volume of 200 μL. Exosomes were injected every week start-
ed at 7 weeks and mice were sacrificed at 10 weeks post-HFD feeding. To 
monitor the exosome trafficking after tail vein injection, exosomes were 
stained by lipophilic PKH26 fluorescent dye (Millipore Sigma, Mini26-
1KT) before injection. Liver and visceral adipose tissue (VAT) sections 
(10 μm) were observed by Nikon A1R confocal microscope.
Primary hepatocyte isolation and culture. Primary hepatocytes were 
isolated from age-matched WT or Trem2–/– male mice using released 
publications as reference (51). Briefly, mice were anesthetized by i.p. 
injection of ketamine/xylazine (100 mg/kg and 10 mg/kg). Livers 
were fully perfused through portal vein with liver perfusion buffer 
and then digested with dispase (Gibco, 17105-041) and collagenase 
type-I (Gibco, 17100-017) for 2 minutes at a rate of 2 mL/min. Then 
liver was excised, minced, and filtered through a 200 μm mesh. Pri-
mary hepatocytes were washed by washing buffer containing 0.1 g/L 
DNase (Sinopharm Chemical Reagent Co., Ltd, 64002860), 0.1 g/L 
MgSO2·7 H2O and 0.1 g/L MgCl2·6 H2O and then separated via cen-
trifugation at 110g for 2 minutes. Primary hepatocytes were cultured 
in the DMEM supplemented with 10% FBS and 1% penicillin-strep-
tomycin in a humidified incubator for 6 hours. The medium was then 
removed and replaced with fresh HepatoZYME-SFM medium (Gibco, 
17705-021) supplemented with 1% l-glutamine (Thermo Fisher Sci-
entific, 25030081) and 1% penicillin-streptomycin for future study.
Cell treatment. mmu-miR-106b-5p mimic or NC were synthesized 
by GenePharma (B02001 or B04003, respectively). In some exper-
iments, miR-106b-5p was labeled with Cy3 before transfection. To 
transfect miRNAs into BMDMs, lipofectamine RNAiMAX reagent 
(Thermo Fisher Scientific, 13778150) was used to package miR-106b-
5p mimic or NC. The transfection efficiencies were validated by qPCR.
For hepatocyte-macrophage coculture experiments, primary hepato-
cytes were isolated as above and seeded in the bottom chamber of tran-
swell culture system with 0.4 mm polycarbonate filter (1.5 × 105 per well; 
Corning, 3413) and rested for 6 hours before use. Different genotype 
BMDMs or WT BMDMs transfected with mimic miR-106b-5p or NC 
were then seeded in the upper chamber (1.5 × 105 per well) and cocultured 
with hepatocytes for 24 hours with 0.5 mM PA in the culture medium.
For exosome treatment experiments, primary hepatocytes isolat-
ed from WT mice were seeded in a 12-well plate (2.5 × 105 per well) 
and treated by 20 μg/mL WT or Trem2–/– BMDM–derived exosomes 
for 12 hours. To determine the Mfn2 expression of hepatocytes, BNL.
CL2 cells were placed in a 12-well plate (2.5 × 105 cells per well) and 
then transfected with miR-106b-5p mimic or NC for 24 hours.
TEM. For mitochondrial ultrastructure, liver tissue was dissected 
and fixed in 2.5% glutaraldehyde overnight at 4°C, post-fixed in 1% 
osmium tetroxide for 80 minutes at 4°C, dehydrated through a graded 
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